

Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer



Key Concepts

Adjuvant Nivolumab Trial

- Adjuvant nivolumab did not improve disease-free survival compared with observation following complete resection and standard adjuvant therapy in patients with high-risk early-stage NSCLC, including the subgroup with high PD-L1 expression ($\geq 50\%$).
- High tumor PD-L1 expression ($\geq 50\%$) was associated with favorable clinical outcomes regardless of treatment assignment, highlighting its prognostic value in resected NSCLC.
- For patients with resectable, high-risk, PD-L1–positive NSCLC, clinical evidence continues to support a perioperative treatment strategy incorporating neoadjuvant chemoimmunotherapy, with or without adjuvant immunotherapy. In contrast to this negative adjuvant-only study, prior perioperative trials have demonstrated meaningful improvements in event-free survival and have established neoadjuvant chemoimmunotherapy as a preferred therapeutic approach for eligible patients.